Drugs / 13-valent pneumococcal conjugated vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01908283 | Mar 2014 → Jun 2016 | Crohn disease, ulcerative colitis | Klara M. Pósfay Barbe | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 13-valent pneumococcal conjugated vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01908283 ↗ |
| Known as | PCV13 (Prevenar13, Pfizer AG, Zurich) | “PCV13 (Prevenar13®, Pfizer AG, Zurich)” NCT01908283 ↗ |
| Modality | Vaccine | “A pneumococcal conjugated vaccine (PCV) was originally developed to protect young children and demonstrated as highly effective and safe.” NCT01908283 ↗ |
| Route | Intramuscular | “PCV13 (1 dose=0.5ml, intra-muscular)” NCT01908283 ↗ |